

## Erratum to: Pazopanib in advanced renal cell carcinoma: a guide to its use in the EU

Katherine A. Lyseng-Williamson<sup>1</sup>

Published online: 9 November 2015  
© Springer International Publishing Switzerland 2015

**Erratum to: Drugs Ther Perspect (2015)  
31:372–377  
DOI 10.1007/s40267-015-0249-2**

The author has alerted us to the following error:

Page 376, section “Compared with sunitinib”, column 2, lines 18–26.

The paragraph that previously read:

‘Dose reductions were required in 44 and 51 % of pazopanib and placebo recipients, respectively, and 44 and 49 % of patients in the respective groups required treatment interruption for  $\geq 7$  days (44 and 49 %) [10]. In the pazopanib group, 24 % of patients prematurely discontinued therapy because of adverse events compared with 20 % in the placebo group; this BGD was primarily due to the proportion of patients in each group who discontinued therapy because of liver-related events (6 vs. 1 %) [10].’

should read:

‘Dose reductions were required in 44 and 51 % of pazopanib and sunitinib recipients, respectively, and 44 and 49 % of patients in the respective groups required treatment interruption for  $\geq 7$  days (44 and 49 %) [10]. In the pazopanib group, 24 % of patients prematurely discontinued therapy because of adverse events compared with 20 % in the sunitinib group; this BGD was primarily due to the proportion of patients in each group who discontinued therapy because of liver-related events (6 vs. 1 %) [10].’

---

The online version of the original article can be found under doi:[10.1007/s40267-015-0249-2](https://doi.org/10.1007/s40267-015-0249-2).

---

✉ Katherine A. Lyseng-Williamson  
dtp@adis.com

<sup>1</sup> Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand